Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.
Author(s): El-Gendy N, Aillon KL, Berkland C
Affiliation(s): Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, United States.
Publication date & source: 2010-05-31, Int J Pharm., 391(1-2):305-12. Epub 2010 Mar 7.
Publication type: Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Aerosolized contrast agents may improve the resolution of biomedical imaging modalities and enable more accurate diagnosis of lung diseases. Many iodinated compounds, such as diatrizoic acid, have been shown to be safe and useful for radiographic examination of the airways. Formulations of such compounds must be improved in order to allow imaging of the smallest airways. Here, diatrizoic acid nanoparticle agglomerates were created by assembling nanoparticles into inhalable microparticles that may augment deposition in the lung periphery. Nanoparticle agglomerates were fully characterized and safety was determined in vivo. After dry powder insufflation to rats, no acute alveolar tissue damage was observed 2h post-dose. Diatrizoic acid nanoparticle agglomerates possess the characteristics of an efficient and safe inhalable lung contrast agent. Copyright (c) 2010 Elsevier B.V. All rights reserved.